Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Cutia Therapeutics ( (HK:2487) ) has issued an update.
Cutia Therapeutics has successfully completed the placement of 28,904,000 new shares under a general mandate, raising approximately HK$240.27 million in net proceeds. The funds will be used to advance the company’s research and development pipeline, particularly in areas such as localized adipose accumulation management and skin diseases, as well as to deploy necessary production facilities and equipment.
The most recent analyst rating on (HK:2487) stock is a Hold with a HK$12.00 price target. To see the full list of analyst forecasts on Cutia Therapeutics stock, see the HK:2487 Stock Forecast page.
More about Cutia Therapeutics
Cutia Therapeutics is a company incorporated in the Cayman Islands, focusing on healthcare solutions. Its primary products and services include pre-clinical research and development, and clinical trials for localized adipose accumulation management, scalp diseases and care, skin diseases and care, and topical anesthesia.
Average Trading Volume: 1,216,890
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$3.18B
See more data about 2487 stock on TipRanks’ Stock Analysis page.